Close Menu

SQI Diagnostics

PerkinElmer reduced its headcount by 109 employees in 2018 as a result of restructuring actions, it said in its Form 10-K filed with the US Securities and Exchange Commission this week.

The company said that three unnamed insiders who are in control of the company are expected to subscribe for most of the securities for sale.

The Toronto-based partners aim to create a rapid, multiplex test and companion point-of-care device for identifying lung transplant candidates.

NeoGenomics said this week it has completed its previously announced acquisition of Genoptix. NeoGenomics said that the acquisition expands its reach into the oncology space and significantly accelerates progress toward its scale and growth objectives.

Microdrop will license the rights to market SQI's celiac and wheat allergy, and arthritis tests direct to consumers.

The company and university will develop a chip and detection devices to enable a wide array of multi-result tests that will be offered directly in clinical settings.